GNPX News and Press, Genprex Inc. From 11/21/19

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company, on Wednesday announced a registered direct offering of 3,167,986 shares of its common stock at a price of $0.40 each, for gross proceeds of about $1.26 million prior to deduction of commissions and offering expenses. In a concurr...

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today a registered direct offering of 3,167,986 shares of...

These 4 Penny Stocks Are Trading Under $2.50; Will They Go Higher Or Lower This Week? With more and more people being employed every month, the economy is feeling very secure at the moment. More consumers have the disposable income to spend which means that the stock market is attracting more ...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company, today announced that its collaborators from The University of Texas MD Anderson Cancer Center (“MD Anderson”) presented positive preclinical data at the American Association of Cancer Research Tumor Immunology and I...

Company’s TUSC2 gene therapy found to increase effectiveness of anti-PD1 immunotherapy and anti-PD1 immunotherapy combined with platinum chemotherapy in humanized mouse model TUSC2 in combination with anti-PD1 and chemotherapy resulted in complete eradication of anti-PD1 resi...

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) today announced that it is publishing lung cancer prevention measures in an effort to educate the public, prevent new cases and raise awareness in support of November’s Lung Cancer Awareness Month. According to the update, eac...

Genprex, Inc. (NASDAQ: GNPX ), a clinical-stage gene therapy company, is publishing lung cancer prevention measures in an effort to educate the public, prevent new cases and raise awareness of lung cancer while supporting November’s Lung Cancer Awareness Month. Each patient ...

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) today announced its plans to present at the upcoming inaugural MicroCap Rodeo Investor Conference to be held at the Hilton Austin - Downtown in Austin, Texas. Genprex’s presentation is scheduled to take place on Tuesday, Octob...

Genprex, Inc. (NASDAQ: GNPX ), a clinical-stage gene therapy company, today announced that it will be presenting at the inaugural MicroCap Rodeo Investor Conference in Austin, Texas on Tuesday, October 15 at 9:10 a.m. CDT. Genprex’s Chairman and Chief Executive Officer, Rodney V...

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) today announced additional research in the field validating non-viral vector delivery as the next evolution in gene therapy. Per the update, a recently published paper titled, “Encapsulation, Visualization and Expression of Ge...